Last $0.04 SGD
Change Today 0.00 / 0.00%
Volume 0.0
PHM On Other Exchanges
Symbol
Exchange
Singapore
As of 4:16 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

pharmesis international ltd (PHM) Snapshot

Open
$0.04
Previous Close
$0.04
Day High
$0.04
Day Low
$0.04
52 Week High
04/10/14 - $0.06
52 Week Low
08/4/14 - $0.03
Market Cap
7.2M
Average Volume 10 Days
23.5K
EPS TTM
$-0.10
Shares Outstanding
200.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMESIS INTERNATIONAL LTD (PHM)

Related News

No related news articles were found.

pharmesis international ltd (PHM) Related Businessweek News

No Related Businessweek News Found

pharmesis international ltd (PHM) Details

Pharmesis International Ltd., an investment holding company, develops, manufactures, and sells western medicines, health tonic products, and traditional Chinese medicine (TCM) formulated products in the People’s Republic of China. The company operates through Western Drugs, TCM Formulated Drugs, and Distribution segments. It is also involved in the wholesale of chemical drugs, biological raw products, TCMs, antibiotics, and antibiotics agents. The company offers its western medicines and TCM formulated products in the form of tablets, granules, pills, etc. Its products comprise Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi tablets for flatus, inappetency, dyspepsy, and spleen weakness; and Lianpu Shuangqing for the treatment of acute inflammation, such as dysentery and intestinal infection. Pharmesis International Ltd. also offers Shulinghou tablets, which clear heat and regenerate body fluid, as well as for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Xiaoluotong Jiaonang for treating rheumatoid arthritis and other rheumatic diseases; and Afenka for the treatment of migrane, pain from headache, cold, nasosinusitis, muscle pain, menstrual pain, toothache, and arthritis. In addition, the company provides Er Ding granules for the treatment of jaundice and heat toxic clearance; Bear Bile and Bulbus Fritillariae oral liquid for the treatment of phlegm-heat cough; and Gansu for the treatment of acute and chronic hepatitis; and Gansu for the treatment of acute and chronic hepatitis. Pharmesis International Ltd. markets its western drugs under the Kinna brand name; and TCM formulated drugs under the Longlife brand name to approximately 2,000 hospitals through its sales and marketing personnel. The company was founded in 1996 and is headquartered in Chengdu, the People’s Republic of China.

Founded in 1996

pharmesis international ltd (PHM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmesis international ltd (PHM) Key Developments

Pharmesis International Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Pharmesis International Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of RMB 14,552,000 against RMB 15,104,000 a year ago. Loss from operations was RMB 1,041,000 against RMB 1,266,000 a year ago. Loss before tax was RMB 356,000 against RMB 1,246,000 a year ago. Loss for the period attributable to equity holders of the company was RMB 119,000 or 0.06 cents diluted per share against RMB 1,135,000 or 0.57 cents diluted per share a year ago. Net cash flows from operating activities were RMB 2,738,000 against RMB 229,000 a year ago. Acquisition of property, plant and equipment was RMB 185,000 against RMB 11,000 a year ago. The group's revenue decreased by RMB 0.5 million or 3.7% mainly due to lower demand for the group's prescribed products namely ATT and Gansu. For the six months, the company reported revenue of RMB 27,986,000 against RMB 30,272,000 a year ago. Loss from operations was RMB 2,818,000 against RMB 2,412,000 a year ago. Loss before tax was RMB 1,482,000 against RMB 2,370,000 a year ago. Loss for the period attributable to equity holders of the company was RMB 578,000 or 0.29 cents diluted per share against RMB 2,140,000 or 1.07 cents diluted per share a year ago. Net cash flows from operating activities were RMB 3,610,000 against RMB 1,856,000 a year ago. Acquisition of property, plant and equipment was RMB 268,000 against RMB 121,000 a year ago. Net asset value per ordinary share as on June 30, 2014 was 45.27 cents.

Pharmesis International Ltd. to Report Q2, 2014 Results on Jul 25, 2014

Pharmesis International Ltd. announced that they will report Q2, 2014 results on Jul 25, 2014

Pharmesis International Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Pharmesis International Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of RMB 13,434,000 compared to RMB 15,168,000 a year ago. Loss from operations was RMB 1,777,000 compared to RMB 1,146,000 a year ago. Loss before tax was RMB 1,126,000 compared to RMB 1,124,000 a year ago. Loss attributable to equity holders of the company was RMB 459,000 or 0.23 per diluted share compared to RMB 1,005,000 or 0.50 per diluted share a year ago. Net cash flows from operating activities were RMB 872,000 compared to RMB 1,627,000 a year ago. Acquisition of property, plant and equipment and construction in progress was RMB 83,000 compared to RMB 110,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHM:SP $0.04 SGD 0.00

PHM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHM.
View Industry Companies
 

Industry Analysis

PHM

Industry Average

Valuation PHM Industry Range
Price/Earnings 17.3x
Price/Sales 0.6x
Price/Book 0.4x
Price/Cash Flow 17.3x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMESIS INTERNATIONAL LTD, please visit www.pharmesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.